Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled "FDA Can Go Ahead With Mobile App Guidance."
Following is an excerpt:
The FDA user fee bill set for a vote in the House on Wednesday will not stop the agency from issuing a final guidance on how it will regulate the booming area of mobile health applications. ?...
The final bill orders the study to be done and reported to Congress, but the agency can move forward with the guidance before that. "[T]hose like the mHealth Regulatory Coalition who acknowledge that FDA has a legitimate role to play wanted to avoid any delay, in the desire to get needed clarity around the scope of FDA regulation," Brad Thompson, mHealth's general counsel and an attorney with EBG, wrote in an email to POLITICO. "We are breathing a sigh of relief."
